Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.

Br J Cancer · 2014 · PMC3960625 · PMID 24518593

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, we noticed that patients with a clinical benefit from Ih-IL-2 showed a trend to having a longer OS compared with patients with PD (median OS in months: PR=42.1 (21.9–53.5), SD=42.3 (19.1–86.2), PD=33.7 (19.2–45.0)).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.